Trump Formally Nominates White House Aide Heidi Overton To Lead FDA
President Trump announced on Wednesday, August 19, 2026, that he will nominate Dr. Heidi Overton as the next FDA commissioner, a choice that requires Senate confirmation.[1]
Overton is deputy assistant to the president for domestic policy and deputy director of the White House Domestic Policy Council, and Trump said she will "work with Secretary Kennedy and Dr. Oz" on health priorities.[1]
Overton trained in medicine and surgery and holds a doctorate in clinical investigation from Johns Hopkins; she also served as a White House fellow and as chief policy officer at the America First Policy Institute.[2] The FDA is currently led by acting commissioner Kyle Diamantas after commissioner Marty Makary resigned in May amid internal tensions over flavored e-cigarette approvals.[1] Overton was in the Oval Office on August 10 when Trump signed an executive order recommending changes to childhood vaccines and urged splitting the MMR shot into three separate doses.[1] She has criticized abortion pills and could seek to roll back FDA rules expanding access to medication abortion, drawing condemnation from Sen. Patty Murray.[2]
Early coverage from CBS and Fox presented Overton mainly by her medical credentials and framed the pick as a standard White House nomination.[3] Later reporting from PBS shifted the tone, highlighting critics' concerns about her abortion-pill views and vaccine policy work.[2]
Show source details & analysis (4 sources)
📌 Key Facts
- On Wednesday, August 19, 2026, President Trump announced he will nominate Dr. Heidi Overton as the next FDA commissioner — a formal nomination that must still be sent to and approved by the Senate (Dr. Heidi Overton).
- Overton currently serves as a deputy assistant to the president for domestic policy and as deputy director of the White House Domestic Policy Council, from which she is moving to the FDA role (White House Domestic Policy Council).
- Her medical and professional credentials include medical school at the University of New Mexico, a general surgery residency and a doctoral degree in clinical investigation from Johns Hopkins University, a past White House fellowship in Trump’s first term, and service as chief policy officer at the America First Policy Institute (Johns Hopkins University).
- The nomination requires confirmation by a narrowly Republican-led Senate; Overton is expected to face questioning from the Senate HELP Committee (chaired by Sen. Bill Cassidy), and the FDA is currently led by acting commissioner Kyle Diamantas after former commissioner Marty Makary resigned in May (Kyle Diamantas).
- Trump said Overton will “work with Secretary Kennedy and Dr. Oz” to advance priorities such as faster cures, clinical-trial reforms, lower drug prices and changes to vaccine policy (Secretary Kennedy).
- Overton was among the small group in the Oval Office on August 10, 2026, when Trump signed an executive order recommending limits and changes to childhood vaccines and advocated splitting the MMR vaccine into three separate shots (executive order).
- Reports note Overton has been critical of abortion pills and, if confirmed, could move to roll back FDA rules that expanded access to medication abortion; Democratic Sen. Patty Murray called her “a far-right, anti-abortion extremist” (Patty Murray).
- Her nomination arrives amid unresolved FDA policy fights left by former commissioner Marty Makary — including ultraprocessed-food definitions, antidepressant safety reviews, COVID-19 vaccine oversight and flavored e‑cigarette regulation — and with the FDA under Health Secretary Robert F. Kennedy Jr. pursuing tougher vaccine-testing hurdles, blocked publications and changes to peptide and food policies (Robert F. Kennedy Jr.).
📰 Source Timeline (4)
Follow how coverage of this story developed over time
August 19, 2026
6:38 PM
Trump picks White House aide Dr. Heidi Overton to lead FDA
New information:
- On Wednesday, August 19, 2026, Trump publicly announced that Dr. Heidi Overton, deputy director of the White House Domestic Policy Council, is his pick to lead the FDA, emphasizing her as a 'rockstar' who will deliver faster cures, innovation, and lower drug prices.
- The article specifies Overton’s background: medical school at the University of New Mexico, a doctoral degree in clinical investigation from Johns Hopkins University, and past service as chief policy officer at the America First Policy Institute.
- PBS details Overton’s recent role promoting Trump health initiatives, including participation in 'most favored nation' drug-pricing deals and standing beside Trump at the August 10, 2026 executive order event where he advocated splitting the MMR vaccine into three separate shots.
- The piece highlights that Overton has been critical of abortion pills and, if confirmed, could move to roll back FDA rules expanding access to medication abortion, a step sought by anti-abortion advocates frustrated with the administration’s inaction on online prescribing.
- PBS notes that Overton will need confirmation from a narrowly Republican-led Senate and will face questioning from the Senate HELP Committee, whose chair, Sen. Bill Cassidy, has criticized Trump’s efforts to sow doubt about vaccinations.
- Democratic Sen. Patty Murray is quoted on social media calling Overton 'a far-right, anti-abortion extremist' and arguing she should not lead the FDA.
- The article recaps unresolved policy fights left by former commissioner Marty Makary, including ultraprocessed foods, antidepressant safety reviews, COVID-19 vaccine oversight, and contentious handling of flavored e-cigarettes and nicotine pouches.
- It reports that under Health Secretary Robert F. Kennedy Jr., the FDA has set extra hurdles for vaccine testing, blocked publication of some COVID-19 shot effectiveness research, and is pursuing an ultraprocessed-food definition and peptide regulation changes aligned with Kennedy’s MAHA movement.
4:45 PM
Trump to nominate Dr Heidi Overton as next FDA commissioner
New information:
- Article published Wednesday, August 19, 2026, at 11:45 a.m. Central, reports that President Trump will nominate Dr. Heidi Overton as the next FDA commissioner.
- The Fox News piece characterizes Overton explicitly as 'Dr. Heidi Overton,' emphasizing her medical credentials as she is moved from the White House Domestic Policy Council to the FDA role.
- The article reaffirms that the decision is to nominate her, meaning a formal nomination still must be sent to the Senate for confirmation.
4:41 PM
Trump nominates policy aide Dr. Heidi Overton as next FDA commissioner
New information:
- On Wednesday, August 19, 2026, President Trump announced he is nominating Dr. Heidi Overton to be FDA commissioner.
- The article details that Overton currently serves as a deputy assistant to the president for domestic policy and has worked closely with HHS Secretary Robert F. Kennedy Jr. and CMS head Dr. Mehmet Oz.
- Trump's Truth Social post says Overton will "work with Secretary Kennedy and Dr. Oz" to advance priorities including faster cures, clinical trial reforms, lower drug prices and vaccine policy changes.
- The piece notes Overton was among the small group present in the Oval Office when Trump signed an August 10, 2026 executive order recommending limits and changes to childhood vaccines.
- CBS specifies that Overton completed a general surgery residency at Johns Hopkins, was a White House fellow during Trump's first term, and will require Senate confirmation to assume the role.
- The article reiterates that acting commissioner Kyle Diamantas is currently leading the FDA after former commissioner Dr. Marty Makary resigned in May over internal tensions about flavored e-cigarette approvals.